Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ: ROIV )

11.00 +0.26 (+2.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
From Roivant Sciences
Via GlobeNewswire
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
From Roivant Sciences
Via GlobeNewswire
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the... 
Via Benzinga
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Via Benzinga
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Via Benzinga
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Via Benzinga
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
From Roivant Sciences
Via GlobeNewswire
Where Roivant Sciences Stands With Analysts
Via Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
Via Benzinga
ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
ROIV stock results show that Roivant Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million. 
Via Benzinga
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Earnings Preview
Via Benzinga
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. 
Via InvestorPlace
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure... 
Via Benzinga
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira. 
Via Investor's Business Daily
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
From Roivant Sciences
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading. 
Via Investor's Business Daily
5 Value Stocks In The Healthcare Sector
Via Benzinga
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
From Roivant Sciences
Via GlobeNewswire
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.